immunoglobulin
ig
supplement
standard
treatment
patient
disord
antibodi
product
due
b
cell
combin
b
cell
abnorm
pidd
regularli
schedul
infus
ig
replac
supplement
antibodi
decreas
risk
seriou
bacteri
viral
infect
experienc
pidd
patient
although
avail
prepar
immun
globulin
provid
suffici
antibodi
significantli
decreas
frequenc
infect
immunodefici
patient
infect
continu
occur
previou
studi
suggest
infect
antibodydefici
pidd
patient
occur
titer
protect
antibodi
inadequ
mani
report
focus
bacteri
pathogen
addit
evid
support
proposit
high
titer
antivir
antibodi
prepar
may
provid
advantag
convent
ig
studi
earli
rsvivig
prematur
infant
demonstr
abil
polyclon
antirsv
hyperimmun
globulin
reduc
respiratori
syncyti
viru
rsv
infect
also
viral
respiratori
infect
well
otiti
media
product
avail
american
academi
pediatr
aap
state
children
sever
immunodefici
receiv
ig
therapi
winter
month
physician
could
consid
addit
andor
substitut
high
titer
rsvivig
standard
ig
supplement
data
suggest
polyclon
antirsv
hyperimmun
globulin
would
confer
enhanc
protect
infect
despit
success
use
rsvivig
prematur
infant
voluntarili
withdrawn
introduct
monoclon
antirsv
antibodi
could
administ
intramuscularli
rather
intraven
requir
polyclon
antibodi
consequ
new
ig
formul
meet
standard
criteria
treatment
pidd
develop
use
plasma
collect
individu
test
high
titer
antirsv
antibodi
present
studi
prospect
openlabel
nonrandom
multicent
phase
studi
usa
evalu
efficaci
safeti
patient
pidd
primari
object
evalu
annual
acut
seriou
bacteri
infect
rate
secondari
object
includ
evalu
miss
day
work
due
infect
unschedul
visit
physician
day
hospit
due
infect
well
safeti
toler
also
studi
pharmacokinet
studi
measur
concentr
total
immun
globulin
also
measur
concentr
antibodi
rsv
cytomegaloviru
cmv
tetanu
toxoid
haemophilu
influenza
type
b
hib
measl
serotyp
streptococcu
pneumonia
investig
new
drug
use
studi
provid
adma
biolog
ramsey
nj
manufactur
sourc
plasma
obtain
approv
donor
screen
blood
born
pathogen
bind
assay
nucleic
acid
test
purchas
obtain
domest
plasma
donat
center
licens
us
fda
certifi
plasma
protein
therapeut
associ
ppta
plasma
pool
lot
includ
suffici
plasma
donor
high
neutral
titer
rsv
meet
standard
valu
manufactur
method
includ
cohnoncley
fraction
follow
ion
exchang
chromatographi
follow
downstream
purif
step
final
product
contain
mgml
protein
least
protein
human
igg
monom
plu
dimer
content
greater
distribut
igg
subclass
final
product
similar
distribut
start
plasma
potenc
product
meet
cfr
criteria
requir
level
antibodi
measl
polio
diphtheria
addit
standard
elev
neutral
titer
rsv
rsv
neutral
titer
lot
use
studi
similar
found
compar
former
product
openlabel
phase
iii
studi
evalu
efficaci
safeti
pharmacokinet
subject
document
pidd
clinicaltrialsgov
intraven
infus
given
studi
center
dose
mgkg
everi
week
approxim
year
dose
interv
determin
subject
prestudi
infus
schedul
infus
rate
began
mgkgmin
increment
increas
everi
min
reach
maximum
mgkgmin
dose
adjust
studi
maintain
minimum
trough
igg
concentr
mgdl
investig
discret
subset
subject
particip
pk
portion
studi
pk
data
analyz
total
igg
concentr
well
specif
antibodi
titer
rsv
cmv
tetanu
hib
measl
serotyp
pneumonia
elig
subject
male
femal
age
year
inclus
confirm
diagnosi
primari
immunodefici
prior
enrol
subject
requir
receiv
ivig
infus
everi
week
dose
chang
mean
dose
mgkg
basi
month
subject
exclud
histori
advers
reaction
blood
bloodderiv
product
select
iga
defici
histori
allerg
reaction
product
contain
iga
antibodi
iga
abnorm
liver
function
deep
vein
thrombosi
hemolysi
posit
coomb
test
pregnant
lactat
primari
efficaci
endpoint
demonstr
seriou
bacteri
infect
sbi
rate
less
per
personyear
treatment
secondari
efficaci
endpoint
includ
incid
infect
kind
number
day
lost
workschoolusu
activ
due
infect
treatment
number
unschedul
visit
physician
due
infect
time
resolut
infect
number
hospit
day
hospit
due
infect
number
day
antibiot
therapi
prophylact
treatment
relationship
among
dose
trough
level
risk
seriou
nonseri
infect
trough
total
igg
specif
antibodi
level
subject
monitor
advers
event
ae
seriou
advers
event
sae
infus
visit
use
subject
diari
ae
defin
untoward
medic
occurr
whether
ae
determin
product
relat
subject
regularli
complet
subject
diari
captur
data
studi
infus
subject
diari
use
captur
incid
durat
infect
sbi
infect
use
antibiot
sick
day
miss
work
school
unschedul
doctor
hospit
visit
due
infect
incid
advers
event
data
review
studi
personnel
studi
visit
confirm
accuraci
complet
tempor
associ
ae
taae
advers
event
occur
within
h
infus
safeti
endpoint
includ
incid
taae
sae
relat
sae
discontinu
studi
treatment
pidd
relat
death
infus
site
reaction
chang
vital
sign
infus
proport
infus
one
taae
chang
laboratori
valu
blood
sampl
pk
analysi
obtain
begin
infus
infus
order
allow
wash
previou
ig
product
schedul
sampl
time
follow
immedi
prior
infus
end
infus
min
h
h
h
day
day
day
day
day
postinfus
pk
paramet
calcul
use
noncompartment
analysi
plasma
concentr
equal
greater
valid
lower
limit
quantit
individu
antibodi
assay
use
analysi
actual
sampl
time
use
pharmacokinet
analys
per
protocol
time
use
calcul
mean
plasma
concentr
graphic
display
calcul
pk
paramet
includ
elimin
constant
k
elimin
halflif
area
curv
auc
dose
interv
total
plasma
clearanc
cl
volum
distribut
vz
level
specif
antibodi
cmv
tetanu
hib
measl
rsv
determin
time
point
intenttotreat
itt
popul
includ
screen
subject
fulfil
elig
criteria
treatment
itt
subject
receiv
least
one
infus
studi
referenc
mitt
primari
popul
efficaci
safeti
analys
pk
popul
includ
mitt
subject
enrol
particip
pk
portion
studi
suffici
plasma
sampl
drawn
deriv
pk
paramet
descript
statist
provid
overal
popul
treatment
regimen
n
mean
sd
minimum
median
maximum
continu
variabl
count
percentag
categor
variabl
infect
identifi
base
report
treatment
emerg
advers
event
map
meddra
infect
infest
system
organ
class
concomit
medic
record
use
identifi
antibiot
medic
base
drug
code
atc
level
rout
indic
annual
rate
per
person
per
year
calcul
total
episod
eg
total
infect
event
total
day
eg
day
lost
due
infect
divid
total
personyear
onesid
upper
bound
annual
rate
estim
gener
linear
model
poisson
distribut
intercept
paramet
quartil
mean
day
resolut
infect
estim
use
kaplanmei
estim
twosid
confid
interv
calcul
use
normal
approxim
continu
correct
proport
infus
taae
total
subject
screen
subject
male
femal
enrol
receiv
least
infus
mitt
popul
major
studi
subject
caucasian
averag
age
year
rang
year
studi
includ
adult
subject
year
age
pediatr
subject
common
pidd
type
common
variabl
immunodefici
cvid
subject
subject
mean
time
diagnosi
studi
enrol
year
rang
year
demograph
characterist
similar
two
regimen
tabl
efficaci
treatment
subject
pidd
age
year
period
efficaci
tabl
demonstr
absenc
sbi
studi
popul
observ
incid
zero
sbi
subject
year
total
studi
day
treatment
result
sbi
rate
criteria
sbi
per
subject
per
year
set
fda
key
efficaci
secondari
endpoint
includ
lost
day
workschooldaycar
due
infect
day
per
subject
per
year
unschedul
emerg
roommed
visit
due
infect
visit
per
subject
per
year
hospit
due
infect
hospit
per
subject
per
year
analysi
trough
concentr
igg
specif
antibodi
demonstr
administr
dose
mgkg
everi
week
gener
maintain
concentr
similar
present
baselin
trough
rsv
titer
howev
except
observ
level
increas
first
infus
remain
elev
throughout
studi
increas
antibodi
level
pathogen
test
observ
subject
receiv
subject
receiv
dose
mgkg
demonstr
even
higher
specif
antibodi
level
pathogen
compar
receiv
dose
mgkg
although
studi
power
identifi
differ
safeti
efficaci
cycl
subject
dose
cycl
observ
higher
trough
igg
concentr
compar
subject
cycl
evid
suggest
differ
efficaci
safeti
outcom
base
treatment
cycl
treatment
cycl
success
maintain
trough
igg
concentr
well
target
threshold
mgdl
mean
igg
trough
level
rang
mgdl
subject
cycl
mgdl
subject
cycl
thirti
subject
subject
infus
cycl
subject
infus
cycl
particip
pk
portion
studi
administr
either
regimen
result
increas
igg
cmv
tetanu
hib
measl
rsv
pneumonia
serotyp
antibodi
greatest
increas
cmax
observ
antibodi
rsv
increas
titer
antirsv
neutral
antibodi
immedi
infus
ivig
increas
subject
receiv
greater
mgkg
tabl
calcul
baselin
valu
antirsv
measur
immedi
prior
entri
trial
figur
show
pharmacokinet
antirsv
antibodi
situat
baselin
valu
antirsv
measur
subject
enrol
pk
portion
studi
immedi
prior
infus
seventh
ninth
dose
ivig
manufactur
contain
standard
elev
level
neutral
antibodi
rsv
lot
test
releas
potenc
rsv
antibodi
level
appar
differ
group
mean
plasma
concentr
igg
mean
valu
cmax
despit
slightli
larger
auc
dose
interv
due
longer
period
although
mean
valu
consid
qualit
period
time
measur
consist
literatur
valu
igg
although
rang
dose
within
group
appar
relationship
auc
dose
interv
either
total
dose
weight
adjust
dose
either
cohort
tabl
taken
whole
increas
rsv
cmv
tetanu
hib
measl
pneumonia
antibodi
affect
treatment
interv
use
studi
mean
valu
antibodi
measur
baselin
compar
preinfus
titer
cohort
maximum
titer
higher
baselin
preinfus
titer
appear
differ
exposur
igg
function
sex
age
group
analysi
baselin
correct
plasma
igg
concentr
result
comparison
cycl
cohort
compar
use
plasma
concentr
without
baselin
correct
well
toler
studi
proport
studi
infus
taae
upper
onesid
confid
limit
indic
studi
met
target
safeti
endpoint
studi
subject
experienc
least
one
taae
taae
experienc
studi
infus
tabl
infus
administ
studi
averag
infus
administ
per
subject
studi
infus
one
complet
plan
two
infus
differ
subject
interrupt
due
ae
complet
next
day
mean
se
plan
weight
adjust
dose
administ
studi
mgkg
rang
mgkg
major
subject
studi
experi
infusionrel
ae
complic
studi
infus
gener
well
toler
infus
administ
maximum
allow
infus
rate
mgkgmin
infus
rate
rang
mgkgmin
studi
use
premed
limit
seven
studi
infus
total
total
infus
seven
subject
seriou
bacteri
infect
occur
studi
total
treatment
emerg
ae
teae
experienc
subject
cours
studi
tabl
frequent
report
teae
regardless
relationship
studi
drug
includ
headach
sinus
diarrhea
viral
gastroenter
nasopharyng
upper
respiratori
tract
infect
total
teae
determin
studi
drug
relat
studi
subject
frequent
report
studi
drugrel
teae
headach
sae
report
trial
attribut
studi
drug
two
seriou
advers
event
sae
report
one
instanc
postop
wound
infect
migrain
neither
sae
associ
studi
drug
event
experienc
singl
occurr
singl
subject
low
incid
advers
infus
reaction
total
event
experienc
subject
infus
frequent
report
event
includ
headach
myalgia
total
four
infus
site
reaction
report
studi
two
subject
infus
site
reaction
report
includ
infus
site
extravas
infus
site
pain
evid
trend
toward
signific
chang
laboratori
assess
treatment
studi
medic
end
studi
laboratori
assess
gener
similar
screen
assess
trend
note
laboratori
evid
instanc
thrombot
event
acut
renal
failur
hemolysi
event
viral
transmiss
asept
mening
transfusionrel
acut
lung
injuri
among
viral
infect
caus
substanti
morbid
respiratori
syncyti
viru
particular
problem
especi
patient
coexist
pulmonari
diseas
antirsv
hyperimmun
globulin
product
rsvivig
approv
prevent
sever
respiratori
syncyti
viru
infect
prematur
infant
whose
gestat
age
less
week
studi
suggest
rsvivig
reduc
diseas
sever
infant
becam
infect
rsv
shorten
hospit
stay
compar
agematch
control
despit
benefici
effect
rsvivig
voluntarili
remov
market
manufactur
favor
intramuscularli
administr
monoclon
antirsv
antibodi
palivizumab
direct
head
head
clinic
studi
compar
efficaci
rsvivig
palivizumab
appear
compar
abil
prevent
rsv
infect
low
birth
weight
infant
appear
certain
clinic
advantag
polyclon
antibodi
prevent
studi
rsvivig
abl
prevent
rsv
infect
also
reduc
incid
nonrsvrel
upper
respiratori
diseas
anoth
studi
demonstr
highrisk
infant
receiv
rsvivig
statist
signific
reduct
overal
frequenc
otiti
media
compar
placebotr
subject
also
suggest
polyclon
antibodi
activ
pathogen
may
contribut
reduct
observ
incid
otiti
media
interestingli
current
studi
one
singl
report
case
otiti
media
exceedingli
low
incid
popul
subject
studi
recent
publish
studi
cotton
rat
demonstr
reduc
viral
load
normal
immun
suppress
cotton
rat
infect
rsv
dramat
revers
intens
inflammatori
chang
observ
pulmonari
tissu
histor
data
suggest
potenti
valu
polyclon
antirsv
ig
product
immunecompromis
patient
popul
new
ig
formul
develop
new
product
ivig
manufactur
standard
contain
elev
level
antirsv
neutral
antibodi
regard
compar
howev
new
product
ad
advantag
manufactur
compli
fda
guidanc
ig
product
treatment
patient
pidd
similar
ig
ivig
made
plasma
collect
plasma
donor
manufactur
use
fdaapprov
fraction
purif
process
unlik
ig
plasma
use
produc
collect
donor
identifi
select
high
neutral
antibodi
titer
rsv
select
base
test
result
obtain
util
valid
rsv
liveviru
microneutr
assay
great
increas
level
antirsv
neutral
antibodi
measur
subject
dose
regimen
greater
mgkg
interestingli
lot
ivig
produc
rsv
hyperimmun
donor
also
found
significantli
elev
antibodi
titer
respiratori
virus
parainfluenza
type
influenza
coronaviru
metapneumoviru
compar
ten
commerci
lot
ig
prepar
therefor
regard
uniqu
antibodi
profil
multipl
respiratori
virus
differenti
commerci
avail
ig
view
context
data
ig
trial
mani
secondari
efficaci
endpoint
exampl
number
day
miss
workschooldaycar
per
subject
per
year
hospit
per
subject
per
year
unschedul
visit
physician
emerg
room
per
subject
per
year
compar
favor
publish
trial
studi
demonstr
excel
outcom
might
reflect
uniqu
antibodi
profil
efficaci
like
result
mainten
stabl
igg
trough
level
well
specif
antibodi
level
throughout
studi
confer
expect
protect
effect
ig
therapi
pharmacokinet
properti
compar
previou
report
ivig
prepar
subject
maintain
averag
trough
level
serum
ig
approxim
mgkg
signific
postinfus
increas
specif
antibodi
titer
measur
greater
increas
seen
concentr
rsvneutral
antibodi
immedi
postinfus
patient
receiv
greater
mgkg
ig
acut
seriou
bacteri
infect
report
singl
infect
requir
hospit
believ
secondari
cat
scratch
infect
recov
postop
shoulder
joint
repair
wound
subject
noncompli
miss
regularli
schedul
dose
safe
well
toler
rate
tempor
associ
treatment
associ
advers
event
well
within
fda
guidanc
compar
rate
advers
event
occur
studi
ivig
product
infus
complet
without
interrupt
discontinu
rate
reduct
infus
two
subject
report
one
sae
postop
wound
infect
migrain
studi
neither
associ
studi
drug
subject
postop
wound
infect
sae
discontinu
studi
wherea
subject
sae
migrain
complet
studi
one
subject
advers
drug
reaction
discontinu
studi
three
discontinu
due
caus
one
subject
becam
pregnant
one
subject
reloc
discontinu
due
sponsor
subject
noncompli
safe
welltoler
highli
effect
immunoglobulin
replac
pidd
manufactur
uniqu
antibodi
profil
donor
popul
test
elev
antirsvneutr
antibodi
titer
unexpectedli
low
rate
infectionrel
outcom
suggest
uniqu
antivir
antibodi
profil
may
import
prevent
infect
pidd
subject
rais
novel
question
role
viral
infect
pathogenesi
infecti
complic
pidd
sinc
report
pulmonari
viral
infect
often
anteced
bacteri
pulmonari
infect
tempt
specul
ivig
high
titer
antibodi
virus
may
also
impact
reduc
incid
bacteri
infect
